-$0.47 Earnings Per Share Expected for Vir Biotechnology (NYSE:VIR) This Quarter – Riverton Roll

December 9th, 2019 7:47 am

Brokerages predict that Vir Biotechnology (NYSE:VIR) will report ($0.47) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Vir Biotechnologys earnings. The firm is scheduled to announce its next earnings report on Tuesday, February 18th.

On average, analysts expect that Vir Biotechnology will report full-year earnings of ($1.81) per share for the current financial year. For the next year, analysts forecast that the company will post earnings of ($1.97) per share, with EPS estimates ranging from ($2.05) to ($1.93). Zacks EPS calculations are a mean average based on a survey of sell-side analysts that follow Vir Biotechnology.

Vir Biotechnology (NYSE:VIR) last announced its quarterly earnings results on Tuesday, November 19th. The company reported ($4.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters consensus estimate of ($3.71) by ($0.89). The business had revenue of $1.40 million for the quarter.

VIR has been the topic of several analyst reports. Barclays initiated coverage on Vir Biotechnology in a report on Tuesday, November 5th. They issued an overweight rating and a $25.00 target price on the stock. Cowen started coverage on shares of Vir Biotechnology in a research report on Tuesday, November 19th. They issued a buy rating on the stock. JPMorgan Chase & Co. started coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. Goldman Sachs Group started coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued a buy rating and a $37.00 price objective on the stock. Finally, Robert W. Baird initiated coverage on shares of Vir Biotechnology in a research report on Wednesday, November 13th. They set a neutral rating for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Vir Biotechnology currently has a consensus rating of Buy and an average target price of $29.00.

Shares of NYSE VIR traded down $0.40 during trading on Tuesday, reaching $12.62. The company had a trading volume of 178,796 shares, compared to its average volume of 158,772. The company has a fifty day simple moving average of $13.53. Vir Biotechnology has a 12 month low of $11.65 and a 12 month high of $16.50.

In related news, major shareholder Endurance (Cayman) Ltd Svf acquired 950,000 shares of the stock in a transaction dated Wednesday, October 16th. The stock was bought at an average price of $14.22 per share, for a total transaction of $13,509,000.00. Also, insider Abu Dhabi Investment Authority bought 1,000,000 shares of the companys stock in a transaction that occurred on Wednesday, October 16th. The shares were bought at an average price of $14.41 per share, for a total transaction of $14,410,000.00.

About Vir Biotechnology

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

StemCell Therapy

-$0.47 Earnings Per Share Expected for Vir Biotechnology (NYSE:VIR) This Quarter – Riverton Roll

Categories

Archives

Recommended Sites

Recent Posts